-
CDK Related Products (487)
Related Products (487)
-
CDK3/CycE1 Recombinant Human Active Protein Kinase
0 ImagesCat. No.: HY-E70678CDK3 is a major player driving retinoblastoma (Rb) phosphorylation during the G0/G1 transition and in the early G1 phase of the cell cycle. CDK3 interacts with various transcription factors involved in cell proliferation, differentiation, and transformation driven by the EGFR/Ras signaling pathway. CDK3/CycE1 Recombinant Human Active Protein Kinase is an ortholog of CDK3.
-
CDK8/CycC Recombinant Human Active Protein Kinase
0 ImagesCat. No.: HY-E70690CDK8 modulates the transcriptional output from distinct transcription factors involved in oncogenic control, including the Wnt/β-catenin pathway, Notch, p53, and transforming growth factor β. Abnormal activity ofCDK8 along with its partner protein cyclin C (CycC) is a common feature of many diseases including colorectal cancer. CDK8/CycC Recombinant Human Active Protein Kinase can be used to study the function of CDK8/CycC.
-
DSS30
0 ImagesCat. No.: HY-147387CAS No.: 883027-32-5DSS30 is a P25/CDK5 inhibitor that reduces β-amyloid (Aβ) secretion by inhibiting amyloid precursor protein lyase 1 (BACEl) phosphorylation. DSS30 can be used in the study of neurodegenerative diseases such as Alzheimer's disease.
-
Anticancer agent 302
0 ImagesCat. No.: HY-185164CAS No.: 3078069-29-8Anticancer agent 302 (Example 1) is an anticancer agent. Anticancer agent 302 has a DC50 value of 199 nM for Cyclin E1 and an IC50 value of 133 nM for pRB. Anticancer agent 302 can be used for tumor research.
-
EGFR/CDK2-IN-3
0 ImagesCat. No.: HY-156115EGFR/CDK2-IN-3 (compound 4b) is a dual inhibitor of EGFR and CDK-2 with IC50s of 71.7 and 113.7 nM, respectively. EGFR/CDK2-IN-3 induces apoptosis in MCF-7 cells and arrests the cell cycle in the S phase. EGFR/CDK2-IN-3 has significant anti-cancer cell toxicity and inhibits MCF-7 with an IC50 of 3.16 μM.
-
CDK9-IN-31
0 ImagesCat. No.: HY-160171CAS No.: 2991074-93-0CDK9-IN-31 (Compound Z1) is a CDK9 inhibitor that inhibits cancer cell growth. CDK9-IN-31 has the potential to be developed as an anticancer agent.
-
CDK/HDAC-IN-1
0 ImagesCat. No.: HY-132914CAS No.: 2762181-73-5CDK/HDAC-IN-1 shows remarkable CDK2/4/6 and HDAC6 inhibitory activity of IC50 = 60.9 ± 2.9, 276 ± 22.3, 27.2 ± 4.2, and 128.6 ± 0.4 nM, respectively.
-
CDK9-IN-38
0 ImagesCat. No.: HY-172582CAS No.: 2773402-44-9
-
EGFR/CDK2-IN-2
0 ImagesCat. No.: HY-156114EGFR/CDK2-IN-2 (compound 6a) is a dual inhibitor of EGFR and CDK-2 with IC50s of 19.6 and 87.9 nM, respectively. EGFR/CDK2-IN-2 induces apoptosis in MCF-7 cells and arrests the cell cycle in the S phase. EGFR/CDK2-IN-2 has significant anti-cancer cell toxicity and inhibits MCF-7 with an IC50 of 0.39 μM.
-
AR/AR-V7 degrader-1
0 ImagesCat. No.: HY-181727AR/AR-V7 degrader-1 is an orally active AR and AR-V7 degrader. AR/AR-V7 degrader-1 disrupts the interaction between AR/AR-V7 and HSP90, leading to their ubiquitination and degradation in castration-resistant prostate cancer cells. AR/AR-V7 degrader-1 regulates the expression of cell cycle-related proteins in prostate cancer cells (downregulates CDK4, CDK6, Cyclin D1, Cyclin E1; upregulates P21) and induces G0/G1 phase arrest. AR/AR-V7 degrader-1 inhibits the proliferation and migration of prostate cancer cells. AR/AR-V7 degrader-1 suppresses the growth of castration-resistant prostate cancer tumors in nude mice and induces the degradation of AR and AR-V7 in tumor tissues. AR/AR-V7 degrader-1 is applicable to the research of castration-resistant prostate cancer.
-
CDK7/CycH/MAT1 Recombinant Human Active Protein Kinase
0 ImagesCat. No.: HY-E70689CDK7/CycH/MAT1 Recombinant Human Active Protein Kinase acts as a cyclin-dependent kinase activating kinase. CDK7 exists in several forms including a core tri-partite CDK7/CycH/MAT1 complex known as CAK (cyclin-dependent kinase activating kinase), as a component in the general transcription factor TFIIH and as a component of larger complexes containing pol II and other transcription factors.
-
MEK-IN-9
0 ImagesCat. No.: HY-179909CAS No.: 871701-39-2
-
P1D-34
0 ImagesCat. No.: HY-171334AP1D-34 is a Pin1 PROTAC degrader with a DC50 value of 177 nM. P1D-34 also down-regulates Pin1 client proteins such as Cyclin D1, Rb, Mcl-1, Akt, and c-Myc. P1D-34 shows anti-proliferative activities in a panel of acute myeloid leukemia (AML) cell lines. P1D-34 induces cell DNA damage and apoptosis by releasing ROS generation. Pink: PIN1 ligand (HY-171442A), Blue: CRBN ligand (HY-14658), Black: Linker (HY-W014883).
-
CDK18/CycY Recombinant Human Active Protein Kinase
0 ImagesCat. No.: HY-E70667CDK18 is a neuronal kinase that phosphorylates TAU protein when overexpressed in human brain. CDK18 shares a conserved PCTAIRE amino acid sequence in the helical α-C region of the kinase N-lobe. CDK18/CycY Recombinant Human Active Protein Kinase is an ortholog of CDK18.
-
CDK1/CycE2 Recombinant Human Active Protein Kinase
0 ImagesCat. No.: HY-E70655CDK1 is a cyclin-dependent kinase that functions as a serine/threonine protein kinase, and is a key player in cell cycle regulation. CDK1/CycE2 Recombinant Human Active Protein Kinase is an ortholog of CDK1.
-
H1k
0 ImagesCat. No.: HY-149261CAS No.: 3039928-21-4H1k, a Eudistomin Y derivative, is a lysosome-targeted antiproliferation agent. H1k increases the autophagy signal and downregulate the expression of cyclin-dependent kinase (CDK1) and cyclin B1. H1k can be used in research of cancer.
-
CDK2/CycE1 Recombinant Human Active Protein Kinase
0 ImagesCat. No.: HY-E70672CDK2 is a cyclin-dependent kinase involved in the control of the cell cycle. CDK2/CycE1 Recombinant Human Active Protein Kinase is an ortholog of CDK2.
